Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Brexafemme® (ibrexafungerp) – New drug approval
June 2, 2021 - SCYNEXIS announced the FDA approval of Brexafemme (ibrexafungerp), for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
